

Pharmacogenomics for Better Treatment of Fungal Infections in Cancer

NCT06510699

Status	RECRUITING
Phase	Phase 2
Sponsor	The University of Queensland
Enrollment	104 participants

Key Eligibility Criteria

Inclusion (5)

- Age ≥ 2 years.
- Written informed consent obtained.
- Decision to prescribe voriconazole.
- Diagnosed with haematological malignancy or disorder.
- Admitted to a trial site, or sufficient outpatient follow-up appointments are feasible

Exclusion (3)

- Post-allogeneic haematopoietic stem cell transplant (HCT) patient, without access to pre HCT DNA
- Death is likely imminent within 7 days.
- Previously randomised to this trial

Locations (7 total)

Fred Hutchinson Cancer Centre, Seattle, Washington, United States
Sydney Children's Hospital Network, Sydney, New South Wales, Australia
Westmead Hospital, Sydney, New South Wales, Australia
... and 4 more locations